Clinical Trial Update: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. [Phase 2]

View source ↗

Summary

A Phase II trial evaluating a combination of atezolizumab, bevacizumab, carboplatin or cisplatin, and pemetrexed in patients with EGFR-mutant metastatic non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: NSCLC Stage IIIB~IV | Phase 2 | Status: COMPLETED